niraparib

Overview

Niraparib is a PARP inhibitor targeting PARP1 and PARP2. It is evaluated in combination with immune checkpoint inhibitors in nasopharyngeal carcinoma (NPC) to exploit DNA repair deficiencies.

Evidence in the corpus

  • Niraparib listed alongside fuzuloparib and olaparib as PARP inhibitors being tested in combination with immune checkpoint inhibitors to exploit DNA repair deficiencies in recurrent/metastatic NPC PMID:24952746.
  • Niraparib directly targets PARP1/PARP2; in BRCA1/2-wild-type mCRPC, resistance to PARP inhibitors (including niraparib) may be driven by high TRMT10A expression, which supports BRCA1 recruitment to DNA double-strand breaks via ATM-mediated Ser28 phosphorylation PMID:28068672

Resistance mechanisms

Cancer types (linked)

Sources

  • PMID:28068672 — Yang et al., TRMT10A/USP10 axis in mCRPC; niraparib named as PARPi class member; high TRMT10A expression tracks with PARPi resistance across the class.

*This page was processed by entity-page-writer on 2026-05-15.